Using <i>N</i>‐Nitrosodiethanolamine (<scp>NDELA</scp>) and <i>N</i>‐Nitrosopiperidine (<scp>NPIP</scp>) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency‐Based Acceptable Intakes for <scp>NDSRIs</scp> Lacking Robust Carcinogenicity Data
Jason M. Roper(Teva Pharmaceuticals (United States)), Valerie Niddam‐Hildesheim(Teva Pharmaceuticals (Israel)), George E. Johnson(Swansea University), Adelina Voutchkova‐Kostal, Raphael Nudelman(Applied Materials (Israel)), Troy Griffin(Teva Pharmaceuticals (United States)), Jakub Kostal(George Washington University), Gregory R. Ott(Teva Pharmaceuticals (United States))
Cited by 5
Related Papers
OxyR
|Cell|2002|474
S-nitrosylation: spectrum and specificity
|Nature Cell Biology|2001|243
Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
|Nature Clinical Practice Rheumatology|2008|197
Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment
|Environmental and Molecular Mutagenesis|2014|147
Quantitative approaches for assessing dose–response relationships in genetic toxicology studies
|Environmental and Molecular Mutagenesis|2012|147